Ottawa, ON / Business Wire/ June 11, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture …Read More
Media
Recent News
-
11
Jun
2021Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants
-
08
Jun
2021Avivagen to Present at LD Micro Conference Presentation on June 10th, at 10:30 A.M. EST
Ottawa, ON / Business Wire/ June 8, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it will be virtually presenting at the …Read More
-
07
Jun
2021Avivagen Inc. Announces Proposed Extension of Warrants and Grant of Options
Ottawa, ON /Business Wire/ June 7, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX …Read More
-
02
Jun
2021Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2021
Second Quarter Highlights: • Record 64.5 tonne order for OxC-betaTM Livestock over 18 months • New expansion efforts and customer wins in Central and South America • Launch of first product for human health. Ottawa, ON /Business Wire/ June 2, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing …Read More
-
07
May
2021Avivagen Terminates Exclusive U.S. Sales and Distribution Agreement
• Agreement with CSA Animal Nutrition to be terminated effective immediately • Avivagen to explore new sales and distributions opportunities to capitalize on significant market opportunity in the United States Ottawa, ON / Business Wire/ May 7, 2021 / –/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products …Read More
Media Coverage
-
Avivagen CEO Interviewed on C-Suite At The Open
Kym Anthony, CEO of Avivagen, was recently interviewed by Karoline Hunter, Head of TSX Company Services at the TMX group.
The interview covered the company story and gives a look ahead at the future of Avivagen’s OxC-BetaTM.
The interview also covers Immune Priming, its powerful anti-inflammatory effect, and its efficacy in improving Gut Health.
-
Copyright © 2021 Avivagen. All Rights Reserved.
